38953-42-3

Basic information

• Product Name: 5-Pyrimidinol, 4-amino-6-chloro- (9CI)
• Synonyms: 5-Pyrimidinol, 4-amino-6-chloro- (9CI);4-Amino-6-chloro-5-pyrimidinol;4-aMino-6-chloropyriMidin-5-ol;4-chloro-5-hydroxy-6-aMinopyriMidine;4-amino-6-chloro-pyrimidinol
• CAS NO: 38953-42-3
• Molecular Formula: C₄H₄ClN₃O
• Molecular Weight: 145.54706
• Product Categories: PYRIMIDINE
• Mol File: 38953-42-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 312.5 °C at 760 mmHg
• Flash Point: 142.8 °C
• Appearance: /
• Density: 1.643
• Vapor Pressure: 0.000287mmHg at 25°C
• Refractive Index: 1.679
• PKA: 4.92±0.20(Predicted)
• CAS DataBase Reference: 5-Pyrimidinol, 4-amino-6-chloro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Pyrimidinol, 4-amino-6-chloro- (9CI)(38953-42-3)
• EPA Substance Registry System: 5-Pyrimidinol, 4-amino-6-chloro- (9CI)(38953-42-3)

Safety Data

• Hazardous Substances Data: 38953-42-3(Hazardous Substances Data)

Usage

General Description

5-Pyrimidinol, 4-amino-6-chloro- (9CI) is a chemical compound with the molecular formula C4H4ClN3O. It is a derivative of pyrimidine and contains an amino group at the 4th position and a chlorine atom at the 6th position. 5-Pyrimidinol, 4-amino-6-chloro- (9CI) is used in the synthesis of various pharmaceuticals and agrochemicals. It has also been studied for its potential anti-cancer and anti-inflammatory properties. Additionally, it has been used in the development of new materials and as a building block for the synthesis of other organic compounds. However, it is important to handle this compound with care and follow safety protocols, as it can pose health and environmental risks if mishandled.

InChI:InChI=1/C4H4ClN3O/c5-3-2(9)4(6)8-1-7-3/h1,9H,(H2,6,7,8)

Upstream product

• 5018-41-7 6-chloro-5-methoxypyrimidine-4-amine 

Relevant articles and documents

Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants

The RET tyrosine kinase is an important therapeutic target for medullary thyroid cancer (MTC), and drug resistance mutations of RET, particularly V804M and V804L, are a main challenge for the current targeted therapy of MTC based on RET inhibitors. In this investigation, we report the structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of RET inhibitors. Among all the obtained kinase inhibitors, 1-(5-(tert-butyl)isoxazol-3-yl)-3-(4-((6,7,8,9-tetrahydropyrimido[5,4-b][1,4]oxazepin-4-yl)amino)phenyl)urea (17d) is a multi-kinase inhibitor and potently inhibits RET and its drug resistance mutants. It showed IC50 (half maximal inhibitory concentration) values of 0.010 μM, 0.015 μM, and 0.009 μM against RET-wild-type, RET-V804M, and RET-V804L, respectively. 17d displayed significant anti-viability potencies against various RET-driving tumor cell lines. In a xenograft mouse model of NIH3T3-RET-C634Y, 17d exhibited potent in vivo anti-tumor activity, and no obvious toxicity was observed. Mechanisms of action were also investigated by Western blot and immunohistochemical assays. Collectively, 17d could be a promising agent for the treatment of MTC, hence deserving a further investigation.

FGFR4 kinase inhibitor, preparation method and uses thereof

The present invention relates to a compound represented by a formula (I), or a pharmaceutically acceptable salt, a solvate, a polymorph or an isomer thereof, and uses in preparation of drugs for treatment of FGFR4 mediated diseases.

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase

Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently marketed covalent BTK inhibitors is limited to oncology indications based on their suboptimal kinase selectivity. We describe the discovery and preclinical profile of LOU064 (remibrutinib, 25), a potent, highly selective covalent BTK inhibitor. LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases. It demonstrates potent in vivo target occupancy with an EC90 of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis. LOU064 is currently being tested in phase 2 clinical studies for chronic spontaneous urticaria and Sjoegren's syndrome.